SEC Form SC 13G filed by Nephros Inc.

2/28/22 12:05:48 PM ET

Medical/Dental Instruments

Health Care

Get the next $NEPH alert in real time by email

SC 13G 1 schedule13gneph.txt UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Nephros, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 640671400 (CUSIP Number) February 24, 2022 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [X] Rule 13d-1(b) [ ] Rule 13d-1(c) [_] Rule 13d-1(d) *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page. The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). SCHEDULE 13G CUSIP No. 640671400 1 Names of Reporting Persons Intelligent Fanatics Capital Management, LLC (EIN 83-1916631) Ian Cassel 2 Check the appropriate box if a member of a Group (see instructions) (a) [ ] (b) [ ] 3 SEC Use Only 4 Citizenship or Place of Organization Intelligent Fanatics Capital Management, LLC - Pennsylvania Ian Cassel - USA Number of Shares Beneficially Owned by Each Reporting Person With: 5 Sole Voting Power 525,408 aggregate shares of Common Stock (see Item 4 below) 6 Shared Voting Power 0 7 Sole Dispositive Power 525,408 aggregate shares of Common Stock (see Item 4 below) 8 Shared Dispositive Power 0 9 Aggregate Amount Beneficially Owned by Each Reporting Person 525,408 aggregate shares of Common Stock (see Item 4 below) 10 Check box if the aggregate amount in row (9) excludes certain shares (See Instructions) [ ] 11 Percent of class represented by amount in row (9) 5.12% 12 Type of Reporting Person (See Instructions) Intelligent Fanatics Capital Management, LLC - IA Ian Cassel - IN Item 1. (a) Name of Issuer Nephros, Inc. (b) Address of Issuer's Principal Executive Offices 380 Lackawanna Place South Orange, NJ 07079 Item 2. (a) Name of Person Filing Intelligent Fanatics Capital Management, LLC Ian Cassel (b) Address of Principal Business Office or, if None, Residence 350 Rumford Road Lititz, Pennsylvania 17543 (c) Citizenship Intelligent Fanatics Capital Management, LLC - Pennsylvania Ian Cassel - USA (d) Title and Class of Securities Common Stock (e) CUSIP No. 640671400 Item 3. If this statement is filed pursuant to Section 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a: (a) [_] Broker or dealer registered under Section 15 of the Act; (b) [_] Bank as defined in Section 3(a)(6) of the Act; (c) [_] Insurance company as defined in Section 3(a)(19) of the Act; (d) [_] Investment company registered under Section 8 of the Investment Company Act of 1940; (e) [x] An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E); (f) [_] An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F); (g) [_] A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G); (h) [_] A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813); (i) [_] A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940; (j) [_] A non-U.S. institution in accordance with Rule 240.13d-1(b)(1)(ii)(J); (k) [_] Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with Rule 240.13d-1(b)(1)(ii)(J), please specify the type of institution: ____ Item 4. Ownership (a) Amount Beneficially Owned: 525,408 aggregate shares of Common Stock may be deemed to be beneficially owned by each Reporting Person. (b) Percent of Class: 5.12% (c) Number of shares as to which such person has: (i) Sole power to vote or to direct the vote: 525,408 aggregate shares of Common Stock (See Item 4a above). (ii) Shared power to vote or to direct the vote: 0 (iii) Sole power to dispose or to direct the disposition of: 525,408 aggregate shares of Common Stock (See Item 4a above). (iv) Shared power to dispose or to direct the disposition of: 0 Item 5. Ownership of Five Percent or Less of a Class. If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [ ]. Item 6. Ownership of more than Five Percent on Behalf of Another Person. This Item 6 is not applicable. Item 7. Identification and classification of the subsidiary which acquired the security being reported on by the parent holding company or control person. This Item 7 is not applicable. Item 8. Identification and classification of members of the group. This Item 8 is not applicable. Item 9. Notice of Dissolution of Group. This Item 9 is not applicable. Item 10. Certifications. By signing below I certify that, to the best of its knowledge and belief, the securities referred to above were acquired and held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect. SIGNATURE After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. Dated: February 28, 2022 /s/ Ian Cassel Name: Ian Cassel Title: Managing Member of Intelligent Fanatics Capital Management, LLC The original statement shall be signed by each person on whose behalf the statement is filed or his authorized representative. If the statement is signed on behalf of a person by his authorized representative (other than an executive officer or general partner of this filing person), evidence of the representative's authority to sign on behalf of such person shall be filed with the statement, provided, however, that a power of attorney for this purpose which is already on file with the Commission may be incorporated by reference. The name and any title of each person who signs the statement shall be typed or printed beneath his signature. Attention: Intentional misstatements or omissions of fact constitute Federal criminal violations (See 18 U.S.C. 1001).

Get the next $NEPH alert in real time by email

SEC Form SC 13G filed by Nephros Inc.

2/28/22 12:05:48 PM ET

$NEPH

Medical/Dental Instruments

Health Care

Get the next $NEPH alert in real time by email

SEC Form SC 13G filed by Nephros Inc.

Crush Q3 2025 with the Best AI Superconnector

Recent Analyst Ratings for
$NEPH

SEC Form SC 13G filed by Nephros Inc.

Crush Q3 2025 with the Best AI Superconnector

Recent Analyst Ratings for
$NEPH

$NEPH
SEC Filings

Nephros Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

SEC Form 10-Q filed by Nephros Inc.

SEC Form 8-K filed by Nephros Inc.

$NEPH
Insider Purchases

Amron Arthur H bought $11,176 worth of shares (5,000 units at $2.24), increasing direct ownership by 5% to 103,463 units (SEC Form 4)

Banks Robert R. Jr. bought $112,050 worth of shares (50,000 units at $2.24), increasing direct ownership by 250% to 70,000 units (SEC Form 4)

Amron Arthur H bought $17,130 worth of shares (7,000 units at $2.45) and acquired 91,463 shares (SEC Form 4)

$NEPH
Press Releases

Nephros Announces Strong Second Quarter Financial Results

Nephros Schedules Second Quarter 2025 Financial Results Conference Call

Nephros to Participate in the Benchmark Company Annual Discovery One-on-One Investor Conference on December 11, 2024 in NYC

$NEPH
Insider Trading

SEC Form 4 filed by Director Nettis Lisa Marie

SEC Form 3 filed by new insider Nettis Lisa Marie

SEC Form 4 filed by Chief Financial Officer Krandel Judy

$NEPH
Analyst Ratings

B. Riley FBR initiated coverage on Nephros with a new price target

$NEPH
Financials

Nephros Announces Strong Second Quarter Financial Results

Nephros Schedules Second Quarter 2025 Financial Results Conference Call

Nephros Announces Financial Results for Quarter Ended September 30, 2024

$NEPH
Large Ownership Changes